PURPOSE: For the treatment of giant cell tumour of the bone (GCTB) around the knee, preserving the native joint confers advantages over scarifying it. But, there is a controversy about the efficacy of intralesional curettage versus en bloc resection for treatment of such lesions. In this study, we compared local recurrence, functional outcomes, and complications of extended curettage and en bloc resection in these lesions. METHODS: Patients with grade 3 GCTB of the distal femur or proximal tibia who were presented with a pathologic fracture and treated with either en bloc resection (n = 22) or extended curettage (n = 20) were included. The mean follow-up of the patients was 6.4 ± 1.9 years in the resection group and 5.5 ± 2.4 years in the extended curettage group. The primary outcome was a local recurrence. Secondary outcomes were limb function evaluated by the Musculoskeletal Tumor Society (MSTS) score and rate of complications. RESULTS: Local recurrence was seen in four (20%) patients of the curettage group and three (13.7%) patients of the resection group (P = 0.69). The mean MSTS score was 24 ± 1.9 in the resection group and 26.5 ± 1.3 in the curettage group (P < 0.001). The number of complications was not significantly different between the two study groups (P = 0.49). However, the number of complications that required revision surgery was significantly more in the resection group (P = 0.049). CONCLUSION: In grade 3 GCTB around the knee with pathologic fracture, extended curettage results in comparable oncologic outcomes to en bloc resection, while providing better function and a lower rate of revision.
PURPOSE: For the treatment of giant cell tumour of the bone (GCTB) around the knee, preserving the native joint confers advantages over scarifying it. But, there is a controversy about the efficacy of intralesional curettage versus en bloc resection for treatment of such lesions. In this study, we compared local recurrence, functional outcomes, and complications of extended curettage and en bloc resection in these lesions. METHODS:Patients with grade 3 GCTB of the distal femur or proximal tibia who were presented with a pathologic fracture and treated with either en bloc resection (n = 22) or extended curettage (n = 20) were included. The mean follow-up of the patients was 6.4 ± 1.9 years in the resection group and 5.5 ± 2.4 years in the extended curettage group. The primary outcome was a local recurrence. Secondary outcomes were limb function evaluated by the Musculoskeletal Tumor Society (MSTS) score and rate of complications. RESULTS: Local recurrence was seen in four (20%) patients of the curettage group and three (13.7%) patients of the resection group (P = 0.69). The mean MSTS score was 24 ± 1.9 in the resection group and 26.5 ± 1.3 in the curettage group (P < 0.001). The number of complications was not significantly different between the two study groups (P = 0.49). However, the number of complications that required revision surgery was significantly more in the resection group (P = 0.049). CONCLUSION: In grade 3 GCTB around the knee with pathologic fracture, extended curettage results in comparable oncologic outcomes to en bloc resection, while providing better function and a lower rate of revision.
Authors: Lizz van der Heijden; P D Sander Dijkstra; Michiel A J van de Sande; Judith R Kroep; Remi A Nout; Carla S P van Rijswijk; Judith V M G Bovée; Pancras C W Hogendoorn; Hans Gelderblom Journal: Oncologist Date: 2014-04-09
Authors: Frank M Klenke; Doris E Wenger; Carrie Y Inwards; Peter S Rose; Franklin H Sim Journal: Clin Orthop Relat Res Date: 2010-08-13 Impact factor: 4.176
Authors: Aarne H Kivioja; Carl Blomqvist; Kalevi Hietaniemi; Clement Trovik; Anders Walloe; Henrik C F Bauer; Peter H Jorgensen; Peter Bergh; Gunnar Follerås Journal: Acta Orthop Date: 2008-02 Impact factor: 3.717
Authors: Carlos Rodriguez-Galindo; Nirali Shah; M Beth McCarville; Catherine A Billups; Michael N Neel; Bhaskar N Rao; Najat C Daw Journal: Cancer Date: 2004-05-01 Impact factor: 6.860
Authors: Lizz van der Heijden; P D Sander Dijkstra; Domenico A Campanacci; C L Max H Gibbons; Michiel A J van de Sande Journal: Clin Orthop Relat Res Date: 2013-03 Impact factor: 4.176
Authors: Benjamin M Deheshi; Shabana N Jaffer; Anthony M Griffin; Peter C Ferguson; Robert S Bell; Jay S Wunder Journal: Clin Orthop Relat Res Date: 2007-06 Impact factor: 4.176
Authors: Maurice Balke; Laura Schremper; Carsten Gebert; Helmut Ahrens; Arne Streitbuerger; Gabriele Koehler; Jendrik Hardes; Georg Gosheger Journal: J Cancer Res Clin Oncol Date: 2008-03-06 Impact factor: 4.553